Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
Kiniksa Pharmaceuticals International cash
Cash and short-term investments held at the end of each period.
Kiniksa Pharmaceuticals International's cash was $568.76M at Sep 30, 2026. For fiscal 2025 it was $414.07M, up 70.0% from the year before. The highest annual figure on record is $414.07M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $414.07M | +70.0% |
| FY2024 | Dec 31, 2024 | $243.63M | +18.1% |
| FY2023 | Dec 31, 2023 | $206.37M | +8.3% |
| FY2022 | Dec 31, 2022 | $190.61M | +4.6% |
| FY2021 | Dec 31, 2021 | $182.20M | -43.7% |
| FY2020 | Dec 31, 2020 | $323.48M | +38.6% |
| FY2019 | Dec 31, 2019 | $233.38M | -24.1% |
| FY2018 | Dec 31, 2018 | $307.30M | +573.0% |
| FY2017 | Dec 31, 2017 | $45.66M | -18.6% |
| FY2016 | Dec 31, 2016 | $56.08M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $568.76M | +61.5% |
| Q2 FY2026 | Jun 30, 2026 | $525.93M | +70.9% |
| Q1 FY2026 | Mar 31, 2026 | $468.09M | +74.4% |
| Q4 FY2025 | Dec 31, 2025 | $414.07M | +70.0% |
| Q3 FY2025 | Sep 30, 2025 | $352.10M | +57.3% |
| Q2 FY2025 | Jun 30, 2025 | $307.78M | +40.7% |
| Q1 FY2025 | Mar 31, 2025 | $268.34M | +25.7% |
| Q4 FY2024 | Dec 31, 2024 | $243.63M | +18.1% |
| Q3 FY2024 | Sep 30, 2024 | $223.78M | +11.3% |
| Q2 FY2024 | Jun 30, 2024 | $218.76M | +18.3% |
| Q1 FY2024 | Mar 31, 2024 | $213.55M | +13.9% |
| Q4 FY2023 | Dec 31, 2023 | $206.37M | +8.3% |
| Q3 FY2023 | Sep 30, 2023 | $201.08M | +0.2% |
| Q2 FY2023 | Jun 30, 2023 | $184.99M | +33.9% |
| Q1 FY2023 | Mar 31, 2023 | $187.49M | +28.8% |
| Q4 FY2022 | Dec 31, 2022 | $190.61M | +4.6% |
| Q3 FY2022 | Sep 30, 2022 | $200.72M | +0.3% |
| Q2 FY2022 | Jun 30, 2022 | $138.21M | -38.8% |
| Q1 FY2022 | Mar 31, 2022 | $145.58M | -44.9% |
| Q4 FY2021 | Dec 31, 2021 | $182.20M | -43.7% |
| Q3 FY2021 | Sep 30, 2021 | $200.18M | -45.1% |
| Q2 FY2021 | Jun 30, 2021 | $225.87M | -10.5% |
| Q1 FY2021 | Mar 31, 2021 | $264.03M | +29.3% |
| Q4 FY2020 | Dec 31, 2020 | $323.48M | +38.6% |
| Q3 FY2020 | Sep 30, 2020 | $364.40M | +40.8% |
| Q2 FY2020 | Jun 30, 2020 | $252.40M | -12.2% |
| Q1 FY2020 | Mar 31, 2020 | $204.21M | -37.5% |
| Q4 FY2019 | Dec 31, 2019 | $233.38M | -24.1% |
| Q3 FY2019 | Sep 30, 2019 | $258.75M | -23.4% |
| Q2 FY2019 | Jun 30, 2019 | $287.45M | -20.0% |
| Q1 FY2019 | Mar 31, 2019 | $326.53M | +47.5% |
| Q4 FY2018 | Dec 31, 2018 | $307.30M | +573.0% |
| Q3 FY2018 | Sep 30, 2018 | $337.86M | +389.4% |
| Q2 FY2018 | Jun 30, 2018 | $359.19M | +348.9% |
| Q1 FY2018 | Mar 31, 2018 | $221.42M | +294.9% |
| Q4 FY2017 | Dec 31, 2017 | $45.66M | – |
| Q3 FY2017 | Sep 30, 2017 | $69.04M | – |
| Q2 FY2017 | Jun 30, 2017 | $80.01M | – |
| Q4 FY2016 | Dec 31, 2016 | $56.08M | – |
See a number that looks wrong?